Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

Canadian business process outsourcing giant Telus Digital has confirmed it suffered a security incident after threat actors claimed to have stolen nearly 1 petabyte of data from the company in a multi ...

Creating a highly accurate geological model at a large scale presents a considerable challenge, primarily due to constraints imposed by sparse data availability. A promising strategy to mitigate these ...

Forbes contributors publish independent expert analyses and insights. Gary Drenik is a writer covering AI, analytics and innovation. This voice experience is generated by AI. Learn more. This voice ...

This log tiny prefab house is filled with all types of beautiful wood and offers the ultimate setup for a tiny house! The manufacturer for this modular house is in partners with Hilltop Structures ...

Global semiconductor giant Advanced Micro Devices Inc. will be the first tenant in a 200-acre data center being developed on a portion of the former Alcoa Corp. smelting site near Rockdale, about 60 ...

Abstract: As an ordered extension of evidence theory, Random permutation set (RPS) theory has received increasing attention due to its advantage in dealing with order-structured uncertain information.

These notes can be used to find top patterns for each category. Note that reading these notes can be much faster than watching videos. Moreover, it can take only take an evening to refresh your ...

Google launched four official and confirmed algorithmic updates in 2025, three core updates and one spam update. This is in comparison to last year, in 2024, where we had seven confirmed updates, then ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...